Dermapharm Holding stock
DMP.DEXETRADermapharm Holding SE, HealthcareISIN DE000A2GS5D8WKN A2GS5D
68Score 68 out of 100, Neutral
Price and trend
59 / 100
Price history
+2.8% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 17% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Sharply down: the price has fallen very quickly lately (RSI 30).
The price is 33% below its 52-week high. Largest decline in 9 years: 67% (November 2021 to October 2024).
Chart figures for advanced users
- SMA 50$42.77
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$46.79
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)30
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$38.28
- The lowest closing price of the last twelve months.
- Resistance$57.64
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Dermapharm Holding SE belongs to the Drug Manufacturers (Specialty & Generic) industry (Germany) and, with a market value of $1.93B, is number 52 of 78 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.3B (down 1.3% year on year) and earnings of $147.33M (up 16.4%).
- For fiscal 2026, analysts expect on average revenue of $1.34B (up 3.2%) and adjusted earnings per share of $2.91 (up 4.7%).
Show more
- MEQIRI Score 68 out of 100 (Neutral): rank 169 of 714 in Healthcare, median 53.
- The P/E is 11.8 (Drug Manufacturers (Specialty & Generic) median 19.3, own median of recent years 20.7).
- Our model puts fair value at $67.23, with the price 36% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 36% below the fair value of $67.23.Valuation 84
- Modestly valuedP/E 11.8, Drug Manufacturers (Specialty & Generic) median 19.3, own median 20.7.Valuation 84
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 90
Weaknesses
- High debtDebt 2.19 times equity (latest quarter), Drug Manufacturers (Specialty & Generic) median 0.49.Stability 55
Its standout strengths are fundamentals and valuation.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 66 to 68.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $51.72 and expensive above $96.04 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $70.81 (cash-flow model) and $63.65 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 7.1%. At 8.1% the fair value would be $61.48, at 6.1% it would be $75.85.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 0.4% on the twelve months before. Revenue has grown solidly since 2014, at about 10% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 34%, operating 19%, net 11%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 12 Nov 2026today
- Last reported
- 25 Aug 2026EPS reported $0.52 (expected $0.52)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $2.910.0%
- Revenue
- $1.34B0.0%
- Earnings per share
- $3.340.0%
- Revenue
- $1.39B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Dermapharm Holding
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 68
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- HUTCHMED (China)HCM $2.63B45
- AlmirallALM.MC $2.61B45
- PerrigoPRGO $2.3B48
- Trulieve CannabisTRLV $2.17B48
- FagronFAGR.BR $1.99B70
- Eton PharmaceuticalsETON $1.97B69
- AlvotechALVO $1.76B43
- Faes FarmaFAE.MC $1.73B71
ETFs that hold Dermapharm Holding
Held by 6 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi SDAX UCITS ETF DistC005 | 0.49% | 0.70% | €157.44M |
| WisdomTree Europe SmallCap Dividend UCITS ETFWTES | 0.42% | 0.38% | €86.74M |
| Vanguard Germany All Cap UCITS ETF (EUR) DistributingVGER | 0.02% | 0.07% | €255.26M |
Show 2 more
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 17 Jul 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.